Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00691717 | Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension | PHASE2 | COMPLETED | 201 | — | — | Jun 1, 2008 | Sep 1, 2009 | Nov 28, 2012 | 1 | United States |
| NCT00451152 | Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma | PHASE2 | COMPLETED | 89 | — | — | Mar 1, 2007 | Jul 1, 2009 | Nov 28, 2012 | 1 | United States |
| NCT00320203 | Anecortave Acetate in Patients With Open-angle Glaucoma | PHASE2 | COMPLETED | 86 | — | — | Mar 1, 2006 | Jan 1, 2008 | Nov 28, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| 24 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye |
| 48 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye |
| 60 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye |
| Anecortave Acetate Vehicle | PLACEBO_COMPARATOR | Single depot administration of 0.8 mL in the study eye |
| Anecortave Acetate Depot | EXPERIMENTAL | - |
| Anecortave Acetate 3 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Anecortave Acetate 15 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Anecortave Acetate 30 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Name | Type | Description |
|---|---|---|
| Anecortave Acetate Sterile Suspension, 30 mg/mL | DRUG | Single administration by anterior juxtascleral depot |
| Anecortave Acetate Sterile Suspension, 60 mg/mL | DRUG | Single administration by anterior juxtascleral depot |
| Anecortave Acetate Sterile Suspension, 75 mg/mL | DRUG | Single administration by anterior juxtascleral depot |
| Anecortave Acetate Vehicle | OTHER | Single administration by anterior juxtascleral depot |
| Anecortave Acetate Sterile Suspension, 6 mg/mL | DRUG | Single injection, anterior juxtascleral depot (AJD) |
Inclusion Criteria: * Patients 18 years of age or older with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation) or ocular hypertension. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patients with any form of glaucoma other than open-angle....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |